KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial A total of 83,419 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback